INmune Bio Inc. (NASDAQ: INMB)
$4.9100
+0.1500 ( +3.15% ) 35.3K
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Market Data
Open
$4.9100
Previous close
$4.7600
Volume
35.3K
Market cap
$106.46M
Day range
$4.7520 - $4.9160
52 week range
$4.4500 - $14.7400
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 19 | Apr 22, 2024 |
| 10-k/a | Quarterly Reports | 17 | Apr 16, 2024 |
| 8-k | 8K-related | 15 | Apr 09, 2024 |
| 8-k | 8K-related | 15 | Mar 29, 2024 |
| 10-k | Annual reports | 82 | Mar 28, 2024 |
| 8-k | 8K-related | 15 | Mar 27, 2024 |
| 8-k | 8K-related | 16 | Jan 30, 2024 |
| 8-k | 8K-related | 14 | Jan 02, 2024 |
| 8-k | 8K-related | 13 | Dec 18, 2023 |
| 8-k | 8K-related | 13 | Dec 18, 2023 |